Pulmonary hypertension in the perioperative period-focus on current and emerging therapies

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Patients with pulmonary hypertension continue to present for both cardiac and non-cardiac surgery in greater numbers worldwide, and are usually managed by cardiothoracic anesthesiologists. These specialists have traditionally used intravenous therapy in the operating room to manipulate hemodynamics (cardiac output systemic and pulmonary vascular resistance), to effectively manage these high risk patients. General anesthesia involves the administration of both intravenous and inhaled drug therapy to achieve the desired goals, i.e. analgesia, amnesia, muscle relaxation and blockade of autonomic activity. Anesthesiologists are the experts in the use and titration of drugs that are administered through the inhaled route. However, this method of drug delivery presents many challenges, notably timing, dosage accuracy, rapid titratability and consistency of drug delivery. In patients with severe pulmonary hypertension, arguably the most rapid method of treating acutely reactive pulmonary vasculature would involve drugs that directly act upon the pulmonary endothelium. In the perioperative period, pulmonary hypertension and right ventricular failure are high predictors of morbidity and mortality and present significant challenges to the anesthesiologist. In this article, we will focus on the current status of intravenous and inhaled therapy of these conditions, including concerned recent patents.

Original languageEnglish (US)
Pages (from-to)38-50
Number of pages13
JournalRecent Patents on Cardiovascular Drug Discovery
Volume9
Issue number1
StatePublished - Dec 1 2014

Fingerprint

Perioperative Period
Pulmonary Hypertension
Pharmaceutical Preparations
Vascular Resistance
Lung
Muscle Relaxation
Amnesia
Patents
Operating Rooms
Therapeutics
Intravenous Administration
Cardiac Output
Analgesia
General Anesthesia
Endothelium
Hemodynamics
Morbidity
Drug Therapy
Mortality
Anesthesiologists

Keywords

  • Inotropes
  • Nitric oxide
  • Pulmonary hypertension
  • Pulmonary vasodilators
  • Right ventricular failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Drug Discovery

Cite this

@article{9613a44f9ba44bf7b140374a527040e8,
title = "Pulmonary hypertension in the perioperative period-focus on current and emerging therapies",
abstract = "Patients with pulmonary hypertension continue to present for both cardiac and non-cardiac surgery in greater numbers worldwide, and are usually managed by cardiothoracic anesthesiologists. These specialists have traditionally used intravenous therapy in the operating room to manipulate hemodynamics (cardiac output systemic and pulmonary vascular resistance), to effectively manage these high risk patients. General anesthesia involves the administration of both intravenous and inhaled drug therapy to achieve the desired goals, i.e. analgesia, amnesia, muscle relaxation and blockade of autonomic activity. Anesthesiologists are the experts in the use and titration of drugs that are administered through the inhaled route. However, this method of drug delivery presents many challenges, notably timing, dosage accuracy, rapid titratability and consistency of drug delivery. In patients with severe pulmonary hypertension, arguably the most rapid method of treating acutely reactive pulmonary vasculature would involve drugs that directly act upon the pulmonary endothelium. In the perioperative period, pulmonary hypertension and right ventricular failure are high predictors of morbidity and mortality and present significant challenges to the anesthesiologist. In this article, we will focus on the current status of intravenous and inhaled therapy of these conditions, including concerned recent patents.",
keywords = "Inotropes, Nitric oxide, Pulmonary hypertension, Pulmonary vasodilators, Right ventricular failure",
author = "Harish Ramakrishna",
year = "2014",
month = "12",
day = "1",
language = "English (US)",
volume = "9",
pages = "38--50",
journal = "Recent Patents on Cardiovascular Drug Discovery",
issn = "1574-8901",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Pulmonary hypertension in the perioperative period-focus on current and emerging therapies

AU - Ramakrishna, Harish

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Patients with pulmonary hypertension continue to present for both cardiac and non-cardiac surgery in greater numbers worldwide, and are usually managed by cardiothoracic anesthesiologists. These specialists have traditionally used intravenous therapy in the operating room to manipulate hemodynamics (cardiac output systemic and pulmonary vascular resistance), to effectively manage these high risk patients. General anesthesia involves the administration of both intravenous and inhaled drug therapy to achieve the desired goals, i.e. analgesia, amnesia, muscle relaxation and blockade of autonomic activity. Anesthesiologists are the experts in the use and titration of drugs that are administered through the inhaled route. However, this method of drug delivery presents many challenges, notably timing, dosage accuracy, rapid titratability and consistency of drug delivery. In patients with severe pulmonary hypertension, arguably the most rapid method of treating acutely reactive pulmonary vasculature would involve drugs that directly act upon the pulmonary endothelium. In the perioperative period, pulmonary hypertension and right ventricular failure are high predictors of morbidity and mortality and present significant challenges to the anesthesiologist. In this article, we will focus on the current status of intravenous and inhaled therapy of these conditions, including concerned recent patents.

AB - Patients with pulmonary hypertension continue to present for both cardiac and non-cardiac surgery in greater numbers worldwide, and are usually managed by cardiothoracic anesthesiologists. These specialists have traditionally used intravenous therapy in the operating room to manipulate hemodynamics (cardiac output systemic and pulmonary vascular resistance), to effectively manage these high risk patients. General anesthesia involves the administration of both intravenous and inhaled drug therapy to achieve the desired goals, i.e. analgesia, amnesia, muscle relaxation and blockade of autonomic activity. Anesthesiologists are the experts in the use and titration of drugs that are administered through the inhaled route. However, this method of drug delivery presents many challenges, notably timing, dosage accuracy, rapid titratability and consistency of drug delivery. In patients with severe pulmonary hypertension, arguably the most rapid method of treating acutely reactive pulmonary vasculature would involve drugs that directly act upon the pulmonary endothelium. In the perioperative period, pulmonary hypertension and right ventricular failure are high predictors of morbidity and mortality and present significant challenges to the anesthesiologist. In this article, we will focus on the current status of intravenous and inhaled therapy of these conditions, including concerned recent patents.

KW - Inotropes

KW - Nitric oxide

KW - Pulmonary hypertension

KW - Pulmonary vasodilators

KW - Right ventricular failure

UR - http://www.scopus.com/inward/record.url?scp=84922271873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922271873&partnerID=8YFLogxK

M3 - Article

C2 - 25345819

AN - SCOPUS:84922271873

VL - 9

SP - 38

EP - 50

JO - Recent Patents on Cardiovascular Drug Discovery

JF - Recent Patents on Cardiovascular Drug Discovery

SN - 1574-8901

IS - 1

ER -